Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Conditions: Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Advanced Gastric Adenocarcinoma; Metastatic Colorectal Adenocarcinoma

Interventions: Drug: ibrutinib; Drug: everolimus; Drug: paclitaxel; Drug: docetaxel; Drug: cetuximab; Drug: pembrolizumab

Sponsors: Pharmacyclics LLC.

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 19, 2023Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments